All News
Where there’s smoke, there’s flare: how pollution fuels RA
Associations between air pollution and disease activity in rheumatoid arthritis have previously been demonstrated. Abstract 0978 sought to determine the association between fire smoke and other pollutant exposures with the risk of RA and RA-associated interstitial lung disease (RA-ILD).
Read Article
The TAPIR study presented at #ACR24 may not be as attention grabbing as others like SELECT-GCA, but in my opinion it is arguablyone of the most important ANCA-vasculitis studies ever. I've shared some further thoughs in an article on @RheumNow https://t.co/mImAE8ezSQ
Richard Conway RichardPAConway ( View Tweet)
RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary
This will change my practice!
#ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA
Janet Pope Janetbirdope ( View Tweet)
What a result!!!
Crowed split 49% against and 51% for MCTD as a unique disease entity
Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group
Fantastic session from all the presenters
@RheumNow #ACR24 https://t.co/GgTVQ1VNWP
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
🔶Clinical Year in Review #ACR24 🔶
Talk By @MHPillingerMD
• Review some of the most impactful studies in Rheumatology from the past year!
#RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
The anti-MCTD group strikes back
Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD
Majority of patients, despite potential overlap, treated for other primary rheum dz
@RheumNow #ACR24 https://t.co/vkQ6UPs34y
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
RCTs are the gold standard in drug research, but rising placebo (PBO) response rates with global recruitment could distort treatment effects. Limited access to care in less affluent countries may be a factor.
#ACR24 @RheumNow ABST#1746 https://t.co/fVeNcw5qwO
Jiha Lee JihaRheum ( View Tweet)
Andreasson et al. High intensity interval training provides greater improvements in exercise capacity than standard moderate intensity training in IIM. @RheumNow #ACR24 Abstr#1735 https://t.co/baj7Cq2QjO https://t.co/yiE1vuk2me
Links:
Richard Conway RichardPAConway ( View Tweet)
Ab1676 discussed an intervention to change patient mindsets about side-effects of #methotrexate. Watch my video for @RheumNow on this abstract here:
https://t.co/NxuxQ5wYda
#ACR24
Mrinalini Dey DrMiniDey ( View Tweet)
On now: The Great Debate - is MCTD a distinct clinical entity?
@DrLisaCS reviews the history of MCTD classification criteria and its evolution
Kasukawa criteria may be most sensitive in one cohort
@RheumNow #ACR24 https://t.co/rDHafZVL1I
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA.
@RheumNow
https://t.co/ospR0qEIsd
Akhil Sood MD AkhilSoodMD ( View Tweet)
Choose Rheum!
Hart & Kumar interviewed trainees about picking rheumatology... major themes:
▶️ exposure prior to medical training
▶️ mentorship/sponsorship
▶️ long-term self-reflection
▶️ chance!
How can we optimize first 3 to build our workforce?
@RheumNow #ACR24 Abst 1738
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop HZ vs. unvaxxed grp
Incidence of PHN was also lower in the vaccinated group (0.2py vs.1.9py)
RZV is effective in preventing HZ & PhN
@Rheumnow #ACR25 abs0977 https://t.co/JhYBYnLmhl
sheila RHEUMarampa ( View Tweet)
2023 @ACRheum guidance recommends #MediterraneanDiet in RA
What are barriers/facilitators to following the diet?
Many pts are willing to try but don't follow it
Barriers➡️ food insecurity & aversions
Many are unaware
Do you talk to your pts about diet?
Ab1673 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
This will change my practice!
#RCT #MMF + #MTX
superior to
#Cyclophosphamide then #Azathioprine
In
#Tayakasu’s #arteritis N=150
RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate
Vs #cyclo ➡️100mg #azathioprine
All got #glucocorticoids
#ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx
Janet Pope Janetbirdope ( View Tweet)
Can we use MTX+MMF to treat active #TAK rather than CYC?
➡️MTX+MMF vs CYC/AZA over 52W
MTX+MMF had:
⬆️Better efficacy in inducing & maintaining remission
❕Comparable safety to CYC/AZA
⏩This combination may prove preferable to using CYC
Ab1696 #ACR24 @RheumNow https://t.co/S0A8YNk3qL
Mrinalini Dey DrMiniDey ( View Tweet)
#Methotrexate is a dud in #PMR for benefit above #glucocorticoids !
#RCT MTX25mg/wk + Pred 15
Mg/d tapered to 0 at 1 yr vs #Prednisone + placebo same taper
NO BENEFIT from #MTX
#1697 #ACR24 @ACRheum @RheumNow
As FYI
Poster at #EULAR observed
#Leflunomide better than #MTX https://t.co/RepBmOKIsA
Links:
Janet Pope Janetbirdope ( View Tweet)
